Page 110 - Read Online

Page 765 Remley et al. Cancer Drug Resist 2023;6:748-67 https://dx.doi.org/10.20517/cdr.2023.63

Immunol 2002;3:991-8. DOI PubMed
79. Gerhard GM, Bill R, Messemaker M, Klein AM, Pittet MJ. Tumor-infiltrating dendritic cell states are conserved across solid human
cancers. J Exp Med 2021;218:e20200264. DOI PubMed PMC
+
80. Dress RJ, Dutertre CA, Giladi A, et al. Plasmacytoid dendritic cells develop from Ly6D lymphoid progenitors distinct from the
myeloid lineage. Nat Immunol 2019;20:852-64. DOI
+
81. Binnewies M, Mujal AM, Pollack JL, et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4 T cell immunity.
Cell 2019;177:556-71.e16. DOI PubMed PMC
82. Oh SA, Wu DC, Cheung J, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer
2020;1:681-91. DOI
83. Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med
2020;12:eaav7431. DOI
84. Ben Addi A, Lefort A, Hua X, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement
of the A receptor. Eur J Immunol 2008;38:1610-20. DOI
2B
85. Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function.
Blood 2008;112:1822-31. DOI PubMed PMC
86. Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for cancer treatment. Cytotherapy
2016;18:1422-34. DOI PubMed
87. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune
defence strategy. Nature 1986;319:675-8. DOI PubMed
88. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016;16:7-19. DOI PubMed
89. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016;17:1025-36.
DOI PubMed
90. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006;6:520-31. DOI PubMed
91. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science
1999;285:727-9. DOI
92. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D
receptor. Nature 2005;436:1186-90. DOI PubMed PMC
93. Barrow AD, Edeling MA, Trifonov V, et al. Natural killer cells control tumor growth by sensing a growth factor. Cell 2018;172:534-
48.e19. DOI PubMed PMC
94. Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal
tumors. Nat Med 2011;17:700-7. DOI
95. Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte
proliferation and survival of cancer patients. Sci Transl Med 2014;6:228ra37. DOI
96. López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell 2017;32:135-54. DOI PubMed
97. O’Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol 2019;19:282-90. DOI PubMed
98. Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-
expressing tumor cells. Blood 2005;106:1711-7. DOI
99. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and
lytic function of activated NK cells. J Immunol 2005;175:4383-91. DOI PubMed
100. Bastid J, Regairaz A, Bonnefoy N, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their
immunosuppressive activity. Cancer Immunol Res 2015;3:254-65. DOI
101. Chatterjee D, Tufa DM, Baehre H, Hass R, Schmidt RE, Jacobs R. Natural killer cells acquire CD73 expression upon exposure to
mesenchymal stem cells. Blood 2014;123:594-5. DOI PubMed
102. Wallace KL, Linden J. Adenosine A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice
2A
with sickle cell disease. Blood 2010;116:5010-20. DOI PubMed PMC
103. Beavis PA, Divisekera U, Paget C, et al. Blockade of A receptors potently suppresses the metastasis of CD73 tumors. Proc Natl
+
2A
Acad Sci U S A 2013;110:14711-6. DOI PubMed PMC
104. Burnstock G, Boeynaems JM. Purinergic signalling and immune cells. Purinergic Signal 2014;10:529-64. DOI PubMed PMC
105. Dangaj D, Bruand M, Grimm AJ, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and
immune attack in solid tumors. Cancer Cell 2019;35:885-900.e10. DOI PubMed PMC
+
106. Duhen R, Fesneau O, Samson KA, et al. PD-1 and ICOS coexpression identifies tumor-reactive CD4 T cells in human solid tumors.
J Clin Invest 2022;132:e156821. DOI PubMed PMC
107. Addeo R, Ghiani M, Merlino F, Ricciardiello F, Caraglia M. CheckMate 141 trial: all that glitters is not gold. Expert Opin Biol Ther
2019;19:169-71. DOI
108. van den Bulk J, Verdegaal EME, Ruano D, et al. Neoantigen-specific immunity in low mutation burden colorectal cancers of the
consensus molecular subtype 4. Genome Med 2019;11:87. DOI PubMed PMC
109. Duhen T, Duhen R, Montler R, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid
tumors. Nat Commun 2018;9:2724. DOI PubMed PMC
110. Aparicio T. PD-1 blockade in tumors with mismatch-repair deficiency. Colon Rectum 2015;9:182-4. DOI